RareSight is raising $2.5M Seed to reach product validation and a major inflection point within 18–24 months, with follow-on funding of approximately $7.5M supporting Phase I FIH studies through 50% cost-sharing and up to 43.5% refundable Australian R&D tax credits, materially reducing net capital required.